Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1A subtype. It has shown positive initial results for the treatment of Raynaud syndrome and dysmenorrhoea, and as a tocolytic, although it is not yet approved for clinical use.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 455170527 | IUPAC_name = 1-({(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-yl}carbonyl)-L-prolinamide | image = Relcovaptan.svg | image_class = skin-invert-image | width = 220
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).